期刊文献+

眼镜蛇毒MP成分与大鼠大脑皮层及心肌M受体结合的亚型选择性研究

The Subtype Selectivity of the MP Component from Chinese Cobra Venom Binding to Muscarinic Receptors of Rat Cerebral Cortex and Myocardial
暂未订购
导出
摘要 目的初步了解眼镜蛇毒MP成分与M受体结合的亚型选择性。方法制备大鼠大脑皮层组织和大鼠心肌组织两种M受体膜蛋白底物。采用放射配体结合法,分别测定眼镜蛇毒MP成分对[3H]QNB与这两种膜蛋白底物结合的抑制百分率和IC50值,分析MP与M受体结合的亚型选择性。结果 MP均能完全抑制[3H]QNB与这两种膜蛋白底物的结合。大鼠大脑皮层组中,MP的抑制行为呈两相式:第Ⅰ相的抑制率为25%,IC50=0.4 nmol·L-1;第Ⅱ相的抑制率为100%,IC50=248.8 nmol·L-1。心肌组MP的IC50值为22.1 nmol·L-1,约为皮层组第Ⅰ相的55倍、第Ⅱ相的1/10。结论 MP对M受体的结合具有亚型选择性。 Objective To investigate the selectivity of the MP component from the venom of Chinese cobra ( Naja atra ) for muscarinic receptor subtypes. Methods The receptor membrane protein substrates from the rat cerebral cortex and rat myocardium were prepared. To evaluate the effect of MP on the binding of [ 3 H ] QNB to the two membrane protein substrates, the inhibition percentage and ICso were respectively determined by radioligand binding assay. Then the subtype selectivity of MP for muscarinic receptors was analyzed. Results The binding of [ 3H ] QNB to the two membrane proteins was inhibited completely by MP. In the rat cerebral cortex group, the inhibition of MP was shown in two phases, In phase Ⅰ , the inhibition percentage was 25% with an ICs0 value of O. 4 nmol ·L^-1. In phase Ⅱ ,the inhibition percentage was 100% with an ICs0 value of 248.8 nmol ·L^-1. In the myocardial group, MP showed complete inhibition with an IC50 value of 22.1 nmol ·L^-1 ,which was about 55 times that in phase I and 10 percent lower than in phase 11 in comparison with the cerebral cortex group. Conclusion The MP component from cobra venom is shown to bind selectively to muscarinic receptor subtypes.
出处 《解放军药学学报》 CAS 2012年第5期385-388,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
基金 福建省青年科技人才创新项目 No.2008F3084
关键词 眼镜蛇毒液 放射配体测定 毒蕈碱受体 亚型选择性 大脑皮层 cobra venom radioligand assay muscarinic receptor subtype selectivity cerebral cortex
  • 相关文献

参考文献11

  • 1Doley R,Kini RM. Protein complexes in snake venom[J].Cellular and Molecular Life Sciences,2009,(17):2851-2871.doi:10.1007/s00018-009-0050-2.
  • 2Nareoja K,Nasman J. Selective targeting of G-protein-coupled receptor subtypes with venom peptides[J].Acta Physiol(Oxf),2012,(02):186-201.
  • 3Servent D,Fruchart-Gaillard C. Muscarinic toxins:tools for the study of the pharmacological and functional properties of muscarinic receptors[J].Journal of Neurochemistry,2009,(05):1193-1202.
  • 4Miyoshi S,Tu AT. A snake venom inhibitor to muscarinic acetylcholine receptor(mAChR):isolation and interaction with cloned human mAChR[J].Archives of Biochemistry and Biophysics,2000,(02):290-295.
  • 5Miyoshi S,Tu AT. Phospholipase A2 from Naja naja sputatrix venom is a muscarinic acetylcholine receptor inhibitor[J].Archives of Biochemistry and Biophysics,1996,(01):17-25.
  • 6Huang LF,Zheng JB,Xu Y. A snake venom phospholipase A2 with high affinity for muscarinic acetylcholine receptors acts on guinea pig ileum[J].Toxicology,2008,(06):1008-1016.
  • 7Adem A,Asblom A,Johansson G. Toxins from the venom of the green mamba Dendroaspis angusticeps that inhibit the binding of quinuclidinyl benzilate to muscarinic acetylcholine receptors[J].Biochimica Et Biophysica Acta,1988,(03):340-345.
  • 8Levey AI. Immunological localization of ml-m5 muscarinic acetylcholine receptors in peripheral tissues and brain[J].Life Sciences,1993,(5-6):441-448.
  • 9史一鸣,钮因尧,陆阳.M受体及相关选择性药物研究进展[J].国际药学研究杂志,2009,36(5):355-361. 被引量:10
  • 10Miyoshi S,Tu AT. Muscarinic acetylcholine receptor(mAChR)inhibitor from snake venom:interaction with subtypes of human mAChR[J].Archives of Biochemistry and Biophysics,1999,(01):114-118.doi:10.1006/abbi.1999.1321.

二级参考文献26

  • 1Caulfield MP, Birdsall NJ. International Union of Pharmacology. ⅩⅦ. Classification of muscarinic acetylcholine receptors [ J ]. Pharmacol Rev, 1998, 50(2) :279 -290.
  • 2Eglen RM. Muscarinic receptor subtype : pharmacology and physiology[ J]. Prog Med Chem, 2005, 43 : 105 - 136.
  • 3Wess J. Novel insights into muscarinic acetylcholine receptor function using gene targeting technology [ J ]. Trends Pharmacol Sci, 2003, 24(8) :414-420.
  • 4Langmead C J, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets[J]. Pharmacol Ther, 2008, 117 (2) :232 -243.
  • 5Mutschler E, Moser U, Wess J, et al. Muscarinic receptor subtypes-pharmacological, molecular biological and therapeutical aspects[J]. Pharm Acta Helv, 1995, 69(4) :243 -258.
  • 6Seifert R, Wieland T. G protein-coupled receptors as drug targets : analysis of activation and constitutive activity [ M ]. Weinheim : Wiley-VCH Press, 2005 : 177 - 193.
  • 7Lu ZL, Saldanha JW, Hulme EC. Transmembrane domains 4 and 7 of the M ( 1 ) muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch [ J ]. J Biol Chem, 2001, 276 ( 36 ) : 34098 - 34104.
  • 8Lu ZL, Hulme EC. The functional topography of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis [ J ]. J Biol Chem, 1999, 274 (11 ) : 7309 - 7315.
  • 9Lu ZL, Hulme EC. A network of conserved intramolecular contacts defines the off-state of the transmembrane switch mechanism in a seven-transmembrane receptor[ J]. J Biol Chem, 2000, 275 (8) :5682 -5686.
  • 10Felder CC. Muscarinie acetyleholine receptors: signal transduetion through multiple effectors [ J ]. FASEB J, 1995, 9 ( 8 ) : 619 - 625.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部